手持质谱仪在数秒内识别出癌组织
|
By Xu Peng, Chief Editor 许鹏 副主编 Posted on 10 Nov 2017 |

图片:手术期间,MasSpec笔快速准确的检测出活癌,有助于改善治疗并减少癌症复发的几率(照片由University of Texas at Austin提供)。
一个由科学家和工程师组成的团队发明了一种强有效的设备,能快速鉴别出癌组织,为外科医生提供精确的诊断信息,决定切除哪些组织,留下哪些组织。
“如果与术后的癌症患者交谈,很多人要说的第一件事是‘我希望外科医生已经切除了全部癌组织’,”Livia Schiavinato Eberlin,University of Texas at Austin(Austin,TX,USA)的助理教授,该研究的设计者和团队领导说,“我们的技术能大大提高外科医生在手术期间真正清除所有痕量癌症的可能性。”
现有的方法冰冻切片分析法,手术期间诊断和确定癌症和正常组织间边界的速度缓慢,有时检测的结果不准确。每份样品检测需要30分钟或更长时间进行准备,并需要由病理学家解读结果,增大患者感染的风险和麻醉的负面作用。一些类型的癌症冰冻切片解读可能困难,经常产生不可靠的结果。
新的MasSpec笔需要花费大约10秒来提供诊断结果,对253份人类癌症患者中取出的组织检测准确度超过96%。还能检测出呈现混合细胞成分的正常组织和癌组织间边界区域中的癌症。
该技术还能为患者提供更安全的手术。“使用该技术,允许我们更精确的切除癌组织,保留正常组织,”项目的合作者,Baylor College of Medicine的James Suliburk说。虽然切除尽可能多的癌症组织很重要,但如果切除太多的健康组织可能产生更大的负面后果。例如,乳腺癌患者可能在麻醉影响的基础上,有更高的风险出现疼痛副作用和神经损伤。甲状腺癌患者可能丧失语言能力或调解体钙水平的能力,而这些能力对于肌肉和神经功能而言是很重要的。
活细胞产生的代谢物,每类癌症产生一套独有的代谢物和其他生物标志物。“由于癌症和正常细胞的代谢物差异很大,我们使用MasSpec笔提取和分析这些代谢物,以获得组织的分子指纹图谱。令人难以置信的是,虽然这种设备简单,检测的化学过程温和,但MasSpec笔能快速提供诊断分子信息,不会造成组织损伤,”Eberlin教授说。
使用MasSpec笔获得一份未知组织样品的分子指纹图谱,可由一个“统计分类器”软件立即进行评价,Eberlin教授和她的同事用253份人类组织样品的分子指纹图谱对该软件进行了培训。样品中包含乳房、肺、甲状腺和卵巢的正常组织和癌性组织。
该笔向组织中加入一滴水,小分子迁移至水中。将水样转移至质谱分析仪中,质谱仪能检测出数千个分子,得出分子指纹图谱。使用该一次性设备仅需简单的握住笔,压在患者的组织上,使用脚踏板触发自动分析,等待数秒就能得到结果。
检测人类样品时,该设备的癌症诊断准确性超过96%。使用该设备还能在手术期间诊断活体、荷瘤小鼠的癌症,不会对组织造成可见的伤害,也不会给动物带来压力。
因此该过程对患者影响小,具备生物相容性。“设计MasSpec笔时,我们确定其接触的组织仍完整,MasSpec笔的塑料头在操作过程中仅加入一滴水,”Zhang教授说。
本研究由Zhang J等人发表在2017年9月6日刊的Science Translational Medicine(科学转化医学期刊)上。
“如果与术后的癌症患者交谈,很多人要说的第一件事是‘我希望外科医生已经切除了全部癌组织’,”Livia Schiavinato Eberlin,University of Texas at Austin(Austin,TX,USA)的助理教授,该研究的设计者和团队领导说,“我们的技术能大大提高外科医生在手术期间真正清除所有痕量癌症的可能性。”
现有的方法冰冻切片分析法,手术期间诊断和确定癌症和正常组织间边界的速度缓慢,有时检测的结果不准确。每份样品检测需要30分钟或更长时间进行准备,并需要由病理学家解读结果,增大患者感染的风险和麻醉的负面作用。一些类型的癌症冰冻切片解读可能困难,经常产生不可靠的结果。
新的MasSpec笔需要花费大约10秒来提供诊断结果,对253份人类癌症患者中取出的组织检测准确度超过96%。还能检测出呈现混合细胞成分的正常组织和癌组织间边界区域中的癌症。
该技术还能为患者提供更安全的手术。“使用该技术,允许我们更精确的切除癌组织,保留正常组织,”项目的合作者,Baylor College of Medicine的James Suliburk说。虽然切除尽可能多的癌症组织很重要,但如果切除太多的健康组织可能产生更大的负面后果。例如,乳腺癌患者可能在麻醉影响的基础上,有更高的风险出现疼痛副作用和神经损伤。甲状腺癌患者可能丧失语言能力或调解体钙水平的能力,而这些能力对于肌肉和神经功能而言是很重要的。
活细胞产生的代谢物,每类癌症产生一套独有的代谢物和其他生物标志物。“由于癌症和正常细胞的代谢物差异很大,我们使用MasSpec笔提取和分析这些代谢物,以获得组织的分子指纹图谱。令人难以置信的是,虽然这种设备简单,检测的化学过程温和,但MasSpec笔能快速提供诊断分子信息,不会造成组织损伤,”Eberlin教授说。
使用MasSpec笔获得一份未知组织样品的分子指纹图谱,可由一个“统计分类器”软件立即进行评价,Eberlin教授和她的同事用253份人类组织样品的分子指纹图谱对该软件进行了培训。样品中包含乳房、肺、甲状腺和卵巢的正常组织和癌性组织。
该笔向组织中加入一滴水,小分子迁移至水中。将水样转移至质谱分析仪中,质谱仪能检测出数千个分子,得出分子指纹图谱。使用该一次性设备仅需简单的握住笔,压在患者的组织上,使用脚踏板触发自动分析,等待数秒就能得到结果。
检测人类样品时,该设备的癌症诊断准确性超过96%。使用该设备还能在手术期间诊断活体、荷瘤小鼠的癌症,不会对组织造成可见的伤害,也不会给动物带来压力。
因此该过程对患者影响小,具备生物相容性。“设计MasSpec笔时,我们确定其接触的组织仍完整,MasSpec笔的塑料头在操作过程中仅加入一滴水,”Zhang教授说。
本研究由Zhang J等人发表在2017年9月6日刊的Science Translational Medicine(科学转化医学期刊)上。
Latest 临床化学 News
Channels
Clinical Chemistry
view channel
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read more
Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
Alzheimer’s disease develops slowly, and biological changes can appear in blood many years before symptoms. While plasma assays for phosphorylated tau offer earlier detection, discerning whether these... Read moreMolecular Diagnostics
view channel
First IVDR‑Certified IGH Clonality Assay Supports Diagnosis of B-Cell Malignancies
Accurate identification of clonal immunoglobulin heavy chain (IGH) gene rearrangements is central to evaluating suspected B-cell lymphoproliferative disorders, where a single B-cell clone yields a defining... Read more
Plasma ctDNA Testing Predicts Breast Cancer Recurrence After Neoadjuvant Therapy
Accurate identification of breast cancer patients at risk of relapse after pre-surgery treatment is central to guiding adjuvant decisions, particularly in aggressive disease. Circulating fragments of tumor... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read more
Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
Early identification of treatment response and relapse remains a major challenge in solid tumors, where minimal residual disease is difficult to detect with routine imaging and blood tests.... Read moreMicrobiology
view channel
WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
Tuberculosis (TB) remains a leading infectious killer, with more than 3,300 deaths and 29,000 new illnesses every day. Diagnostic delays and dependence on centralized laboratory networks continue to impede... Read more
Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Accurate and rapid identification of bacterial infections remains challenging in acute care, where delays can hinder timely, targeted therapy. Infectious diseases are a major cause of mortality worldwide,... Read more
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read more
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read moreTechnology
view channel
Online Tool Supports Family Screening for Inherited Cancer Risk
Genetic test results in oncology often have implications for relatives who may share inherited cancer risk. Many health systems lack structured processes to help patients alert family members, limiting... Read more
Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
Pneumonia is commonly confirmed with chest X-rays or laboratory assays that can take hours, delaying clinical decisions in acute and outpatient settings. Breath-based diagnostics promise faster answers... Read moreIndustry
view channel
Integrated DNA Technologies Expands into Clinical Diagnostics
Integrated DNA Technologies (IDT; Coralville, Iowa, USA) has announced the launch of Archer FUSIONPlex-HT Dx and VARIANTPlex-HT Dx. This launch marks the company’s first in vitro diagnostic (IVD) offerings... Read more








